Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Expert Subcommittee on Cost-Effectiveness Assessments to Begin Discussions this Month: Policy Planning Director Sakoi
May 11, 2012
- Japan’s Application for Membership in PIC/S Reported: PIC/S General Meeting
May 11, 2012
- Risk Management Plans Must Be Submitted By 1 Month Prior to Launch: MHLW Notification
May 8, 2012
- Gov’t, Industry Leaders to Meet on May 10 for Second Dialogue on 5-Year Medical Innovation Strategy
May 8, 2012
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
- CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
- IPV Vaccination Set to Begin in September; Adequate Supplies Expected
April 25, 2012
- Drug Discovery Support Network to Be Coordinated by NIBIO: 5-Year Strategy for Medical Innovation
April 25, 2012
- Medicoeconomic Assessment Should Initially Be Used in Reevaluating Existing Drugs: Dr Fukuda of NIPH
April 24, 2012
- HTA Should Be Used for NHI Drug Pricing, Not Reimbursement: Prof. Endo at DPJ Hearings
April 24, 2012
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
- MHLW Aims to Begin IPV Vaccination in September: Health Minister Komiyama
April 23, 2012
- MHLW Issues Improvement Order to Pfizer for GMP Violation at US BVL Plant
April 20, 2012
- PAL Amendment: Proposal Emerges to Submit Legislation by Diet Members for Third Party Organization
April 19, 2012
- Discussions on Use of Cost-Effectiveness Assessments to Begin with Advanced but Costly Technologies: MED Director Suzuki
April 19, 2012
- DPJ Working Team to Hold Hearings on Cost-Effectiveness Assessments, Pricing of Long-Listed Drugs on April 20
April 19, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…